The review of Net Profit Marginwitnessed a fluctuating trend. The Net Profit Margin moved from39.18% in 2019 to 3.62% in 2023.
The average EBIT Margin for the period under analysis was 25.82%, with 2023 and 2019 performing the worst and best, respectively.
In the current year, PFIZER was able to cover its interest liabilities 9.87 times – compared to 2019 when it was 4.29 times.
The Asset turnover stood at 0.27 times in 2023 from 0.25 in 2019,implying a high performance on Assets of the business in relation to revenue.
Profitability
The revenue of PFIZER has fluctuated year on year. The revenue increased by 1.82% between 2019 and 2020 and a further 23.43% increase was recorded between 2021 and 2022. There also occurred adecrease of –41.70% between 2022 and 2023 (the current period).
Pfizer’s performance in profitability looks bad as the return on capital employed also recorded bad performance during the period of analysis.
Liquidity
The company’s result in liquidity looks poor, as current ratio decreased from 1.22:1 to 0.91:1 on the last year. Which implies that the company does not have enough assets to settle its current liabilities.
Capital Structure
Pfizer is both equity and debt financed.
The debt-to-equity (D/E) ratio has been falling year on year. The gearing position of the company appears to be high as it stood at 81% in the current year.
